The combination of GHRH and GHRP acts on two different receptor systems that converge on GH secretion. GHRH stimulates GH gene transcription and vesicle exocytosis through the GHRH receptor. Ipamorelin amplifies the exocytosis signal through GHS-R1a. In animal models, the combination produces GH output significantly greater than either compound alone — a well-documented synergistic effect.1

CJC NO DAC/Ipamorelin Blend
This blend combines CJC-1295 (No DAC) and Ipamorelin—two research peptides that act synergistically on the growth hormone (GH) axis. CJC-1295 stimulates GH-releasing hormone (GHRH) receptors, while Ipamorelin targets ghrelin receptors. Their combined use supports investigation into pulsatile GH secretion and downstream effects in cellular and endocrine research models.
Product Overview
The CJC NO DAC/Ipamorelin Blend combines a GHRH analog (CJC-1295 without DAC) with a GHRP (Ipamorelin) in a single vial. This combination targets the two complementary arms of growth hormone release: CJC-1295 (no DAC) stimulates GH synthesis and release at the pituitary through the GHRH receptor, while Ipamorelin amplifies the release signal through the ghrelin receptor (GHS-R1a).
The "no DAC" designation is important: CJC-1295 exists in two forms — with and without Drug Affinity Complex. The DAC version binds to albumin for extended half-life. The no-DAC version has a shorter duration, producing GH release patterns that more closely mimic natural pulsatile secretion. The no-DAC form is preferred in research protocols studying physiological GH release dynamics.

Mechanism and Experimental Context
The no-DAC formulation produces short-duration GH pulses rather than sustained elevation, making this blend suitable for studying the physiology of pulsatile GH secretion — the natural pattern in which GH is released in bursts throughout the day rather than continuously.2
The blend serves as a reference point for comparing dual-pathway GH stimulation against individual secretagogues (Ipamorelin alone, Sermorelin alone, Tesamorelin alone) in GH release assays.
Keep the Research Trail Moving
Source Literature
Bowers CY. "Synergistic release of growth hormone by GHRP and GHRH." Journal of Clinical Endocrinology & Metabolism, 2004.
Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006. PubMed: PMID 16352683
Batch Documentation
Current published batch documentation is surfaced on-page whenever the provider exposes a public COA asset.

Frequently Asked Questions
Questions About CJC NO DAC/Ipamorelin Blend
A combination of CJC-1295 (no DAC), a GHRH analog, and Ipamorelin, a selective GHRP. They target complementary GH release pathways for synergistic growth hormone secretion in research models.
DAC = Drug Affinity Complex. CJC-1295 with DAC binds to albumin for extended duration. Without DAC, it has a shorter half-life and produces GH pulses more similar to natural secretion patterns. The no-DAC form is preferred for pulsatile GH research.
They stimulate GH through different receptors. GHRH (via GHRH receptor) drives GH synthesis and release. GHRP (via ghrelin receptor) amplifies the release signal. Together, they produce more GH than either alone — a documented synergistic effect.
Ipamorelin alone stimulates GH release through the ghrelin receptor. Adding CJC-1295 provides simultaneous GHRH receptor stimulation. The combination produces higher peak GH levels and a more robust secretory response in animal models.
No. Research compound for laboratory use only.
Lyophilized at 2-8°C or -20°C. Protect from light.
Each component independently tested via HPLC and LC-MS. COA downloadable on this page.
5mg total. Check product specifications for individual component ratios.
Every Batch Tested by an Independent Lab
We publish the Certificate of Analysis for every product. See our full testing process.



